Advertisement

Implications of Placebos and Nocebos in Clinical Practice

  • Dimos D. MitsikostasEmail author
Chapter
Part of the Headache book series (HEAD)

Abstract

The majority of unwanted adverse events and symptoms (AEs) reported by patients in randomized clinical trials (RCTs) often are not caused by the medication, because the same AEs also occur in the placebo group of the study, referring as nocebo AEs. Nocebo also occurs in clinical practice were switching from brand name to generic may also increase AEs leading to treatment discontinuation. Patients’ expectations are important determinants of nocebo, treatment outcomes, and adherence. The proportion of patients displaying nocebo behaviors in RCTs for migraine and tension-type headache (TTH) prevention has been estimated up to 43% and 24%, respectively; in addition, 5% of placebo-treated patients discontinued treatment because of AEs (nocebo dropouts) for both conditions. As someone could expect, in real life nocebo is even higher reaching 58% and 54%, respectively. On the other hand, placebo plays an essential positive role in therapeutics for all primary headache disorders, reaching up to 45% in RCTs for headaches, but there is no assay to estimate placebo in clinical practice. To improve headache outcome, physicians should limit nocebo and enhance placebo. There is evidence that nocebo effects can be minimized and even reversed by conditioning with verbal suggestion; thus doctor-patient communication and relation display substantial importance, together with other factors including age, gender, personality, previous medical experiences, media and Internet information, treatment price, treatment’s safety profile, and speed of dose titration that are fully summarized in this article.

Keywords

Migraine Tension-type headache Cluster headache Nocebo Treatment Adverse events Patients’ needs Doctor-patient communication 

References

  1. 1.
    Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146(3):261–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Barefoot JC, Brummett BH, Williams RB, Siegler IC, Helms MJ, Clapp-Channing NE, Mark DB. Recovery expectations and long-term prognosis of patients with coronary heart disease. Arch Intern Med. 2011;171:929–35.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Bartels DJP, van Laarhoven AIM, Stroo M, Hijne K, Peerdeman KJ, Donders ART, van de Kerkhof PCM, Evers AWM. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. PLoS One. 2017;12(9):e0182959.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Benedetti F, Amanzio M. The placebo response: how words and rituals change the patient’s brain. Patient Educ Couns. 2011;84(3):413–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Benedetti F, Lanotte M, Lopiano L, Colloca L. When word are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Bingel U. Avoiding Nocebo effects to optimize treatment outcome. JAMA. 2014;312:693–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Chavarria V, Vian J, Pereira C, Data-Franco J, Fernandes BS, Berk M, Dodd S. The placebo and Nocebo phenomena: their clinical management and impact on treatment outcomes. Clin Ther. 2017;39(3):477–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011;73:598.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Colloca L. Nocebo effects can make you feel pain. Science. 2017;358:44.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Colloca L. Placebo, nocebo, and learning mechanisms. Handb Exp Pharmacol. 2014;225:17–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Conn VS, Ruppar TM, Enriquez M, Cooper PS. Patient-centered outcomes of medication adherence interventions: systematic review and meta-analysis. Value Health. 2016;19(2):277–85.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia. 2008;28(10):1003–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Dodd S, Schacht A, Kelin K, Dueñas H, Reed VA, Williams LJ, Quirk FH, Malhi GS, Berk M. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 2015;76(6):702–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. Health Policy. 2014;116(2–3):214–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Dunne SS, Shannon B, Cullen W, Dunne CP. Perceptions and attitudes of community pharmacists towards generic medicines. J Manag Care Spec Pham. 2014;20(11):1138–46.Google Scholar
  17. 17.
    GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRefGoogle Scholar
  18. 18.
    Greville-Harris M, Dieppe P. Bad is more powerful than good: the nocebo response in medical consultations. Am J Med. 2015;128:126–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22–33.PubMedGoogle Scholar
  20. 20.
    Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein R. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5:el5591.CrossRefGoogle Scholar
  23. 23.
    Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012;81(5):312–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Klosterhalfen S, Kellermann S, Braun S, Kowalski A, Schrauth M, Zipfel S, Enck P. Gender and the nocebo response following conditioning and expectancy. J Psychosom Res. 2009;66(4):323–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kroon Van Diest AM, Ernst MM, Slater S, Powers SW. Similarities and differences between migraine in children and adults: presentation, disability, and response to treatment. Curr Pain Headache Rep. 2017;21(12):48.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Le K, Yu D, Wang J, Ali AI, Guo Y. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain. 2017;18(1):69.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2005;25:124–31.PubMedCrossRefGoogle Scholar
  28. 28.
    McCormack JP, GM MD, Virani AS. Is bigger better? An argument for very low starting doses. CMAJ. 2011;183:65–9.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Meister R, Jansen A, Härter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis. J Affect Disord. 2017;215:288–98.PubMedCrossRefGoogle Scholar
  30. 30.
    Mitsikostas DD. Nocebo in headache. Curr Opin Neurol. 2016;29(3):331–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012;12:132–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Mitsikostas DD, Deligianni CI. Q-no: a questionnaire to predict nocebo in & outpatients seeking neurological consultation. Neurol Sci. 2015;36:379–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Mitsikostas DD, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E, Constantinidis T, Dermitzakis M, Vikelis M. Hellenic headache society. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017;18(1):102.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol. 2012;19(5):672–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014;215(1):82–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011;31:550–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012;259:436–47.PubMedCrossRefGoogle Scholar
  38. 38.
    Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816–28.PubMedCrossRefGoogle Scholar
  39. 39.
    Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Reuter U, Sanchez del Rio M, Carpay JA, Boes CJ, Silberstein SD. GSK headache masters program: placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia. 2003;23:496–503.PubMedCrossRefGoogle Scholar
  41. 41.
    Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52:99–113.PubMedCrossRefGoogle Scholar
  42. 42.
    Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology. 2017;88(23):2216–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, Rosano GM. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928–32.PubMedCrossRefGoogle Scholar
  44. 44.
    Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur J Neurol. 2013;20:527–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37(10):965–78.PubMedCrossRefGoogle Scholar
  47. 47.
    Tinnermann A, Geuter S, Sprenger C, Finsterbusch J, Büchel C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science. 2017;358(6359):105–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334–55.PubMedCrossRefGoogle Scholar
  49. 49.
    Woolley JM, Bonafede MM, Maiese BA, Lenz RA. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399–408.PubMedCrossRefGoogle Scholar
  50. 50.
    Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S. Analysis of nocebo effects of antiepileptic drugs across different conditions. J Neurol. 2016;263(7):1274–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Zis P, Shafiq F, Mitsikostas DD. Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials. Seizure. 2017;45:95–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.1st Neurology Department, Aeginition HospitalNational and Kapodistrian University of AthensAthensGreece

Personalised recommendations